DOM-INDAPAMIDE TABLETS 1.25MG 1.25 MG
INDAPAMIDE : 1.25 MG · DIN 02239913 · DOMINION PHARMACAL
Health Canada status: CANCELLED POST MARKET
What is DOM-INDAPAMIDE TABLETS 1.25MG?
DOM-INDAPAMIDE TABLETS 1.25MG 1.25 MG contains INDAPAMIDE : 1.25 MG. It is listed in the Health Canada Drug Product Database under DIN 02239913, held by DOMINION PHARMACAL, supplied as TABLET for ORAL administration. Health Canada currently lists it as cancelled post market, status dated 10-Oct-2018. Nexara Health is a licensed Canadian wholesale distributor (DEL 3-002896-A) and can source this product for hospitals, pharmacies and clinics. Availability and lead time are confirmed per order.
What is DOM-INDAPAMIDE TABLETS 1.25MG used for?
Dom-INDAPAMIDE (indapamide) is indicated in the management of essential hypertension. It may be tried as a sole therapeutic agent in the treatment of mild to moderate hypertension. Normally Dom-INDAPAMIDE, as other diuretics, is used as the initial agent in multiple drug regimens.
Authorized indication as written in the Health Canada product monograph. For healthcare professionals and licensed purchasers; this is not medical advice.
What else is DOM-INDAPAMIDE TABLETS 1.25MG called?
The same molecule, INDAPAMIDE, is registered under other names elsewhere. Buyers and prescribers searching from outside Canada — or working from a foreign prescription or tender document — often know it by one of these:
| Name | Script | Registered in |
|---|---|---|
| Natrilix SR | Latin | Australia, Bahrain, South Africa |
| Adco-Dapamax | Latin | South Africa |
| APO-Indapamide SR | Latin | Australia |
| Dapa-Tabs | Latin | Australia |
| Daptril | Latin | South Africa |
| Hydro-Less | Latin | South Africa |
| Indalix | Latin | South Africa |
| Insig | Latin | Australia |
| Odaplix SR | Latin | Australia |
| ADEX | Latin | Morocco |
| Catexan | Latin | South Africa |
| Cipla Indapamide | Latin | South Africa |
| DAPAMIX SR | Latin | Bahrain |
| DIURIMAT | Latin | Morocco |
| FLUDEX | Latin | Morocco |
Names are taken from national medicine registers and published price lists. A product registered abroad is not authorized for sale in Canada unless it holds its own DIN; import is possible only through the routes Health Canada permits.
Product details and regulatory record
| DIN | 02239913 |
|---|---|
| Brand name | DOM-INDAPAMIDE TABLETS 1.25MG |
| Generic / active ingredient | INDAPAMIDE : 1.25 MG |
| Manufacturer | DOMINION PHARMACAL |
| Strength | 1.25 MG |
| Dosage form | TABLET |
| Route of administration | ORAL |
| Schedule | Prescription |
| ATC code | C03BA11 INDAPAMIDE |
| AHFS class | 40:28.24 |
| Biosimilar | No |
| Health Canada status | CANCELLED POST MARKET |
| Status date | 10-Oct-2018 |
| Original market date | 1999-09-15 00:00:00 |
How is this product identified?
Purchase orders, customs paperwork and tender documents each ask for a different identifier, and a DIN written without its leading zeros is the single most common reason an order line fails to match. Every form Nexara accepts for this product is listed here.
| DIN (8-digit, as used in Nexara ordering) | 02239913 |
|---|---|
| DIN (unpadded, as printed on some documents) | 2239913 |
| Brand name | DOM-INDAPAMIDE TABLETS 1.25MG |
| Active ingredient / INN | INDAPAMIDE : 1.25 MG |
| ATC code | C03BA11 |
| ATC anatomical main group | C — Cardiovascular system |
| ATC therapeutic subgroup | C03 |
| AHFS class | 40:28.24 |
| Health Canada schedule | Prescription |
| Biosimilar biologic | No |
| Market authorization holder | DOMINION PHARMACAL |
How is it stored and handled?
Store between 15°C-30°C
How is it supplied?
HDPE bottles of 30 and 100 tablets and blister packs of 30 tablets
Which pack is which?
| Strength on the label | 1.25 MG |
|---|---|
| Dosage form | TABLET |
| Route | ORAL |
| Packaging as described in the monograph | HDPE bottles of 30 and 100 tablets and blister packs of 30 tablets |
| Storage | Store between 15°C-30°C |
One DIN can cover more than one pack size, and the pack — not the DIN — is what gets priced, shipped and invoiced. Before an order line is unambiguous Nexara needs the strength, the pack size and the presentation, because this listing covers more than one of them.
What can be used instead?
Other Canadian products sharing ATC code C03BA11 INDAPAMIDE. 4 of 28 DINs in this group are currently marketed — marketed products are listed first, because that is what can actually be bought. These tables describe supply, not clinical equivalence: substitution rests with the prescriber or pharmacist, and interchangeability is determined provincially.
| Product | Strength | Form | Manufacturer | Health Canada status | DIN |
|---|---|---|---|---|---|
| APO-INDAPAMIDE 1.25 MG TABLETS | 1.25 MG | TABLET | APOTEX INC | MARKETED | DIN 02245246 |
| APO-INDAPAMIDE 2.5MG TABLETS | 2.5 MG | TABLET | APOTEX INC | MARKETED | DIN 02223678 |
| MYLAN-INDAPAMIDE | 1.25 MG | TABLET | MYLAN PHARMACEUTICALS ULC | MARKETED | DIN 02240067 |
| MYLAN-INDAPAMIDE | 2.5 MG | TABLET | MYLAN PHARMACEUTICALS ULC | MARKETED | DIN 02153483 |
| DOM-INDAPAMIDE TABLETS 2.5MG | 2.5 MG | TABLET | DOMINION PHARMACAL | CANCELLED POST MARKET | DIN 02239917 |
| INDAPAMIDE | 1.25 MG | TABLET | SANIS HEALTH INC | CANCELLED POST MARKET | DIN 02445824 |
| INDAPAMIDE | 2.5 MG | TABLET | SANIS HEALTH INC | CANCELLED PRE MARKET | DIN 02365324 |
| INDAPAMIDE | 2.5 MG | TABLET | SANIS HEALTH INC | CANCELLED POST MARKET | DIN 02445832 |
| INDAPAMIDE HEMIHYDRATE 1.25MG - TAB | 1.25 MG | TABLET | PROVAL PHARMA DIVISION OF SERVIER CANADA INC | CANCELLED POST MARKET | DIN 02227339 |
| INDAPAMIDE HEMIHYDRATE TAB 2.5MG | 2.5 MG | TABLET | PROVAL PHARMA DIVISION OF SERVIER CANADA INC | CANCELLED POST MARKET | DIN 02049341 |
Who else supplies INDAPAMIDE worldwide?
Nexara tracks national medicine registries and published price lists across multiple markets. INDAPAMIDE appears in 129 registered pack listings across 13 markets, published on 10 different national price bases. Where a Canadian route is closed, that is where an alternative route of supply starts — subject to the import rules in both countries.
Registered listings are not stock. Ask us to confirm what can actually be sourced for your order.
How much does INDAPAMIDE cost around the world?
INDAPAMIDE is listed on 11 national price registers Nexara tracks, across 75 pack listings published on 9 different price bases. What each country publishes is set out below.
| Market | What that country publishes | Brands listed | Pack listings | As of |
|---|---|---|---|---|
| South Africa | single exit price | 13 | 17 | 01 Sep 2026 |
| Morocco | PPV (public price) | 10 | 13 | 05 Sep 2026 |
| Australia | ex-manufacturer | 5 | 10 | 08 Sep 2026 |
| Italy | prezzo al pubblico (classe A) | 8 | 10 | 02 Sep 2026 |
| United States | acquisition | 2 | 8 | 03 Sep 2026 |
| United Arab Emirates | public | 4 | 4 | 31 Aug 2026 |
| Hungary | producer price (ex-factory) | 4 | 4 | 03 Sep 2026 |
| Saudi Arabia | public | 4 | 4 | 01 Sep 2026 |
| Bahrain | retail (max) | 2 | 2 | 01 Sep 2026 |
| United Kingdom | hospital | 2 | 2 | 31 Aug 2026 |
| Greece | producer price (ex-factory) | 1 | 1 | 03 Sep 2026 |
Why there are no figures here. These bases are not comparable. A Brazilian ex-factory ceiling, a Belgian pharmacy public price and a Japanese reimbursement rate answer three different questions, and none of them is what a product lands in Canada for. Putting them side by side would mislead in both directions, so Nexara publishes where a molecule is listed and on what basis, and quotes the delivered Canadian price per order.
Can this still be bought in Canada?
No. This Drug Identification Number is cancelled post market in Health Canada's Drug Product Database, so the product is no longer authorized for sale in Canada and Nexara does not supply it. This page is kept as a regulatory record.
If you are looking for a current equivalent, the alternatives above list every product sharing this therapeutic class, with the marketed ones first. Ask us to source an alternative
Ordering questions
Who can buy this from Nexara?
Licensed entities only. Nexara holds Health Canada establishment licence DEL 3-002896-A and ships only to a licensed address.
Is there a minimum order?
Yes, set per product line and per pack multiple rather than on the order total, so you are never asked to buy a part-pack. The minimum for this line is confirmed with your quote.
What is the lead time?
Confirmed per order at quotation, and it depends on current stock position and whether the product is in shortage.
Can Nexara supply this for a clinical trial?
Yes — comparator and background-therapy supply, including sourcing from other markets where a Canadian pack will not satisfy the protocol. Clinical trial supply.